Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026

RIGEL PHARMACEUTICALS INC

Lilly elected to terminate the License and Collaboration Agreement for ocadusertib on April 16, 2026; effective June 15, 2026.
Rigel will regain full rights to ocadusertib and associated RIPK1 inhibitors after termination.
CNS disease program under the agreement was already terminated effective November 2025.
Rigel does not expect to receive any future milestones or royalties under the terminated agreement.
Rigel is evaluating the impact; no financial guidance or changes provided.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

RIGEL PHARMACEUTICALS INC terminated License and Collaboration Agreement with Eli Lilly and Company valued at Lilly's election to terminate the License and Collaboration Agreement in its entirety; Rigel expects (effective 2026-06-15).

Action: termination
Agreement: license
Counterparty: Eli Lilly and Company
Value: Lilly's election to terminate the License and Collaboration Agreement in its entirety; Rigel expects
Effective: 2026-06-15

Exact text from the filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

View on SEC.gov

Browse all material agreements →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.